

Hepatitis A Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brands: Havrix[®] and Vaqta[®] • Inactivated whole virus • Adjuvant: aluminum hydroxide; Vialstopper, syringe cover or syringe plunger may contain latex; See package insert for location and other contents 	
Route	<ul style="list-style-type: none"> • Route: IM (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) Note: Havrix[®] should not be administered into the gluteal region due to suboptimal response. 	
Dose	<ul style="list-style-type: none"> • Vaqta[®] (6 months-18 years): 25 units (0.5 mL) • Havrix[®] (6 months-18 years): 720 EL.U. (0.5 mL) 	
Indications	<ul style="list-style-type: none"> • All children and adolescents, aged ≥ 1 year • If aged 6-11 months, dose prior to departing United States plus 2 doses, aged 12-23 months, separated by 6-18 months 	
Administration Schedule	Dose	Recommended Interval
	Havrix [®] #1 Vaqta [®] #1	First dose of either brand at 1 to 18 years
	Havrix [®] #2 Vaqta [®] #2	Havrix [®] : 6 to 12 months after dose #1 Vaqta [®] : 6 to 18 months after dose #1
Contraindications	<ul style="list-style-type: none"> • Serious allergic reaction to prior dose or vaccine component • Moderate or severe acute illness 	
Special Considerations	<ul style="list-style-type: none"> • Consider simultaneous immune globulin administration if person is traveling to highly endemic area sooner than 4 weeks after administration • Close contact of international adoptee (e.g., household or regular babysitting), within 60 days of arrival from country with high or intermediate endemic hepatitis A (administer dose 1 as soon as adoption is planned, at least 2 weeks before adoptee's arrival) • You may interchange brands • DO NOT restart series, no matter how long since previous dose 	
<p>VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hep-a.html Additional education may be found at www.health.mil/hepA</p>		